Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

main

BREAKING NEWS D Ct Rules BPCIA 180day Notice is Mandatory for Apotexs pegfilgrastim product Grants P

BREAKING NEWS: D. Ct. Rules BPCIA 180-day Notice is Mandatory for Apotex’s pegfilgrastim product, Grants Preliminary Injunction in Amgen v. Apotex | Insights & Resources | Goodwin

BREAKING NEWS: D. Ct. Rules BPCIA 180-day Notice is Mandatory for Apotex’s pegfilgrastim product, Grants Preliminary Injunction in Amgen v. Apotex

Related Content

CHMP Adopts Positive Opinion for Ranibizumab Biosimilars VISLYFA and REXATILUX

Eli Lilly Expands Vaccine Portfolio by Acquiring Three Developers

FDA Approves Shanghai Henlius Biotech IND for Cetuximab Biosimilar

FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria; Janssen Seeks a Preliminary Injunction to Block Their Launch

International Biosimilars Updates

Third Circuit Affirms Denial of Stelara Biosimilar Injunction

FDA Approves Lannett, Lanexa Biologics, and Sunshine Lake Pharma’s Interchangeable Insulin Glargine Biosimilar

FDA Issues Draft Guidance on Safety Testing for Gene Editing Therapies

Goodwin Named an LMG Life Sciences Life Cycle Firm for the Fourteenth Consecutive Year

Goodwin Named Venture Capital Firm of the Year, Hatch-Waxman Litigation Firm of the Year and Life Cycle Firm of the Year at the 2024 LMG Life Sciences Americas Awards

Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year

LMG Recognizes Goodwin Lawyers and Practices for Excellence in Life Sciences

Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.

Goodwin Named an LMG Life Sciences Life Cycle Firm for the Tenth Consecutive Year

Goodwin Adds Life Sciences and Healthcare Litigation Partner William Jackson

China's Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?

Life Sciences

Hatch-Waxman, Biologics and Biosimilars Litigation